/** Caplin Point Q4 FY26 Earnings: Strong Margins, Bigger Sterile Ambitions, and a Cash-Backed Capex Run */

Caplin Point Q4 FY26: Strong margins, bigger sterile ambitions, and a cash-backed capex run

Caplin Point Laboratories ended Q4 FY26 with another quarter of growth while holding on to high profitability. Consolidated revenue from operations rose to INR 600.16 crore, up 19.4% year on year. EBITDA increased to INR 232.60 crore, up 20.0%, and profit after tax came in at INR 172.88 crore, up 19.0%. The company’s operating model continued to show its defining trait: growth does not appear to be coming at the cost of margins.

For FY26, revenue from operations stood at INR 2,187.19 crore, up 12.9% over FY25. EBITDA rose 17.9% to INR 876.39 crore, and PAT rose 20.1% to INR 649.73 crore. The year was also positioned by management as one where balance sheet compounding continued. The CFO highlighted operating cash flow of INR 523 crore and pointed to a growing liquidity pool, with cash of INR 1,471 crore and liquid assets of INR 2,726 crore.

The quarter in numbers and what it signals

Q4 FY26 margins stayed within the tight band the company has maintained over multiple periods. Gross margin on revenue from operations was 59.2%, EBITDA margin was 37.0%, and PAT margin was 27.5%. While gross margin dipped slightly versus the prior quarter, operating profitability remained resilient, supported by scale and cost discipline.

A key point from management commentary was that Caplin’s investments are being pursued without leverage. The chairman reiterated the intent to remain debt-free even as the company continues building new sterile infrastructure, automation systems, and backward integration capabilities.

Emerging Markets: steady engine, with Mexico and Chile moving from planning to execution

Caplin’s Emerging Markets business remains the core. In the revenue mix slide for FY26 operating revenue, the company reported LATAM at 76% and Africa at 21%, with the US shown at 3%. Within Emerging Markets, management disclosed a 75% generic and 25% branded generic mix, and channel mix of 45% wholesale, 20% retail and 35% institutional.

The quarter’s update on Mexico and Chile was specific, and it helps frame where incremental growth could come from in FY27 and beyond. In Mexico, the company said it has received approvals for 25 products and has a pipeline of over 120 products to be filed in the next 18 months. It also stated it has won 11 general and oncology products for tenders over the next 24 months, with a total value of USD 4 million.

In Chile, the company stated it holds 135 plus product licenses, with several more under review or in the pipeline. It also said it has won 15 products for tenders with supplies over the next 24 months, totaling around USD 10 million. On the concall, management added that it is evaluating acquisition candidates for distribution companies in Chile, describing the private market as the most important channel across its geographies.

One quarter’s growth in Emerging Markets can be influenced by tender execution timing. This was visible in the concall discussion on regional growth and receivables. The CFO attributed an unusually strong quarter in Latin America partly to significant tender supplies shipped close to INR 50 to 55 crore to El Salvador.

Regulated markets: Caplin Steriles scaling, own-label profitability, and a larger sterile pipeline

The US business and broader regulated market push is increasingly a second growth engine. The presentation stated that Caplin Steriles Limited’s current split between B2B and B2C is 75% and 25%. It also disclosed that the company received 10 ANDA approvals in FY26 and acquired 15 ANDAs from third parties, taking the ANDA tally to 59, a jump of 25 ANDAs over FY25.

Management’s commentary reinforced that the ANDA expansion is intended to add depth, not just count. The vice-chairman described coverage across sterile formats including vials, pre-filled syringes, IV bags, ophthalmic dropper bottles, cartridges, and now Blow Fill Seal. The company also stated it has filed 54 products in multiple non-US markets, with 32 approved, across Canada, EU, Australia, Mexico, Brazil, South Africa, Saudi and UAE, and that it plans to file 50 plus products in these regions over the next 18 months. Meaningful revenue from these markets was expected in FY27, as per the presentation.

Caplin Steriles USA, the front-end initiative for the company’s own label, is now a measurable contributor. The chairman stated it achieved profitability within its first year of operations, and the vice-chairman said own-label revenue nearly touched INR 100 crore in the first full year, with 30 products launched and another 15 planned in the coming year. On the call, management set an internal target to reach close to INR 200 crore of own-label revenue in the coming year. They also stated that this scaling did not lead to de-growth in the B2B business.

The company also shared profitability for Caplin Steriles. Management stated CSL’s EBITDA for FY26 was INR 142 crore, an EBITDA margin of 30%, compared to INR 102 crore and 27.9% in the prior year. For Q4, management stated CSL EBITDA margin was 33%.

Capex, backward integration, and automation: building for the next cycle

Caplin’s investment narrative is centered on expanding sterile capacity, stepping into complex technologies, and backward integrating key inputs. The strategic investments table in the presentation lays out a multi-project plan. It includes an oncology facility at SIDCO Kakkalur for OSD and injectables marked as completed, an oncology API facility at Thervoy SIPCOT with civil activity completed and a timeline of Q4 FY27, an OSD facility at Puducherry with civil activity ongoing and timeline Q1 FY28, and a COL injectable facility at Gummidipoondi for injectables and ophthalmics with timeline Q4 FY27.

The presentation also stated an enhanced capex budget of approximately INR 1000 crore plus, with around 50% nearing completion and the balance expected over the next 2 to 3 years. The company said this capex would be financed solely through internal accruals and that it expects to remain net cash positive throughout.

On the concall, the CFO quantified the near-term remaining capex: about INR 510 crore is identified to be spent over the next 18 to 24 months. This included already capitalized assets, CWIP, and advances for imported equipment. Management also mentioned additional future plans not included in this number, such as Mexico, Chile warehouses, and quality control laboratories.

Backward integration was discussed across APIs and clinical capabilities. The Emerging Markets highlight slide stated that the Vizag API unit has received manufacturing licenses and completed validations for 4 APIs, with plans to complete validations for 12 more APIs before the end of the year. For the Thervoy oncology API unit, the company stated validations are expected by Q3 FY27, and first DMT filings are planned in FY28.

R&D spending and capability building remain a visible priority. The company disclosed five dedicated R&D setups, three DSIR approved, and stated cumulative capex investment of over INR 870 crore over the last five years toward manufacturing and R&D capabilities. It also stated total R&D spend, including capex and opex, was 15.5% of FY26 PAT. FY26 R&D expense was shown as INR 101 crore, about 4.6% of operating revenue.

A distinct management theme was automation and compliance through digital systems. The chairman described a visual SOP ecosystem, including a patent filing, and spoke about factory digitalization through video-based qualification and institutional learning. The presentation referenced a patent-pending Project Visual Integration with a stated vision to go live within three months across the CSL site.

What to watch next

The call did not provide formal company-wide guidance, but it contained multiple time-bound statements. Management highlighted the remaining capex schedule, the expected ramp-up from non-US regulated markets in FY27, and product filing activity. For the US business, management said it expects Caplin Steriles growth to sustain, and also stated it sees 25% to 30% growth next year for the overall Caplin Steriles business. Own-label revenue had a stated internal target to nearly double.

Investors will likely track three operational markers. First is the execution of sterile capacity build-out, including IV bag expansion and COL-II completion timelines. Second is monetization of the expanded ANDA base through launches, particularly the acquired ANDAs. Third is working capital movement, because receivables were discussed in detail and management indicated a preference range of 100 to 120 days, while explaining current quarter distortions driven by a profitable tender.

Caplin’s FY26 narrative was consistent with its long-standing positioning: a cash-generative Emerging Markets franchise, and a regulated markets platform expanding into complex sterile technologies. The next phase depends less on building intent and more on commissioning timelines, regulatory execution, and the pace at which the US and other regulated markets move from scaling to becoming a larger share of consolidated revenue.